A Canadian Evidence-Based Guideline for the First-Line Treatment of Follicular Lymphoma: Joint Consensus of the Lymphoma Canada Scientific Advisory Board

Clinical Lymphoma, Myeloma and Leukemia - Tập 15 Số 2 - Trang 59-74 - 2015
John Kuruvilla1, Sarit Assouline2, David C. Hodgson1, David MacDonald3, D. A. Stewart4, Anna Christofides5, Marina Komolova5, Joseph Connors6
1Department of Medical Oncology, University of Toronto and Princess Margaret Hospital, Toronto, Ontario, Canada.
2Department of Oncology, McGill University and Jewish General Hospital, Montreal, Quebec, Canada.
3Division of Hematology, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada.
4Departments of Oncology and Medicine, University of Calgary and Tom Baker Cancer Centre, Calgary, Alberta, Canada.
5New Evidence, Toronto, Ontario, Canada.
6Division of Medical Oncology, University of British Columbia and BC Cancer Agency, Vancouver, British Columbia, Canada. Electronic address: [email protected].

Tóm tắt

Từ khóa


Tài liệu tham khảo

International Lymphoma Study Group, 1997, A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project, Blood, 89, 3909, 10.1182/blood.V89.11.3909

Anderson, 1998, Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project, Ann Oncol, 9, 717, 10.1023/A:1008265532487

Ganti, 2005, Follicular lymphoma: expanding therapeutic options, Oncology (Williston Park), 19, 213

Rueda, 2012, Has the time to come leave the “watch-and-wait” strategy in newly diagnosed asymptomatic follicular lymphoma patients?, BMC Cancer, 12, 210, 10.1186/1471-2407-12-210

Perry, 2013, Classification of non-Hodgkin lymphoma in six geographic regions around the world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project [abstract], Hematol Oncol, 31, 120

Canadian Cancer Society. Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics. Canadian Cancer Society. Available at: http://www.cancer.ca/∼/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/canadian-cancer-statistics-2013-EN.pdf. Accessed March 18, 2014.

Canadian Cancer Society. Canadian Cancer Statistics. Available at: http://www.cancer.ca/en/cancer-information/cancer-101/canadian-cancer-statistics-publication/?region=on. Accessed March 18, 2014.

Armitage, 2005, Staging non-Hodgkin lymphoma, CA Cancer J Clin, 55, 368, 10.3322/canjclin.55.6.368

Solal-Céligny, 1998, Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial, J Clin Oncol, 16, 2332, 10.1200/JCO.1998.16.7.2332

Jaffe, 2009, The 2008 WHO classification of lymphomas: implications for clinical practice and translational research, Hematology Am Soc Hematol Educ Program, 523, 10.1182/asheducation-2009.1.523

Solal-Céligny, 2004, Follicular lymphoma international prognostic index, Blood, 104, 1258, 10.1182/blood-2003-12-4434

Federico, 2009, Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project, J Clin Oncol, 27, 4555, 10.1200/JCO.2008.21.3991

Kenkre, 2012, What is the best initial therapy for a patient with symptomatic low-grade follicular lymphoma?, Cancer J, 18, 383, 10.1097/PPO.0b013e31826aed6d

Czuczman, 2006, Controversies in follicular lymphoma: “who, what, when, where, and why?” (not necessarily in that order!), Hematology Am Soc Hematol Educ Program, 303, 10.1182/asheducation-2006.1.303

Fisher, 2005, New treatment options have changed the survival of patients with follicular lymphoma, J Clin Oncol, 23, 8447, 10.1200/JCO.2005.03.1674

Zelenetz, 2013, Non-Hodgkin's lymphomas, version 1.2013, J Natl Compr Canc Netw, 11, 257, 10.6004/jnccn.2013.0037

Dreyling, 2011, ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 22, vi59, 10.1093/annonc/mdr388

McNamara, 2012, Guidelines on the investigation and management of follicular lymphoma, Br J Haematol, 156, 446, 10.1111/j.1365-2141.2011.08969.x

Zinzani, 2013, SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma, Am J Hematol, 88, 185, 10.1002/ajh.23372

López-Guillermo, 2011, Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma, Leuk Lymphoma, 52, 1, 10.3109/10428194.2011.629897

Alberta Health Services. Alberta Health Services. Lymphoma. Clinical Practice Guideline LYHE-002 (version 8). Available at: http://www.albertahealthservices.ca/hp/if-hp-cancer-guide-lyhe002-lymphoma.pdf. Accessed August 9, 2014.

British Colombia Cancer Agency. Cancer management guidelines. Malignant lymphoma. British Colombia Cancer Agency, 2013. Available at: http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Lymphoma/HD/default.htm. Accessed August 9, 2014.

Sabio R. Canadian guideline needed for the treatment of follicular lymphoma (Available at: http://www.newevidence.com/oncology/entries/Canadian_Guideline_Needed_for_the_Treatment/). Accessed: June 23, 2014.

National Comprehensive Cancer Network. NCCN categories of evidence and consensus. Available at: http://www.nccn.org/professionals/physician_gls/categories_of_consensus.asp. Accessed: March 18, 2014.

Pugh, 2010, Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis, Cancer, 116, 3843, 10.1002/cncr.25149

Michallet, 2013, Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?, J Hematol Oncol, 6, 45, 10.1186/1756-8722-6-45

Campbell, 2010, Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy, Cancer, 116, 3797, 10.1002/cncr.25117

Wilder, 2001, Long-term results with radiotherapy for stage I-II follicular lymphomas, Int J Radiat Oncol Biol Phys, 51, 1219, 10.1016/S0360-3016(01)01747-3

Frank, 2001, Centroblastic-centrocytic non-Hodgkin's lymphoma stage I-III: patterns of failure following radiotherapy, Strahlenther Onkol, 177, 597, 10.1007/PL00002370

Ha, 2003, Central lymphatic irradiation for stage I-III follicular lymphoma: report from a single-institutional prospective study, Int J Radiat Oncol Biol Phys, 57, 316, 10.1016/S0360-3016(03)00592-3

Guadagnolo, 2006, Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy, Int J Radiat Oncol Biol Phys, 64, 928, 10.1016/j.ijrobp.2005.08.010

Guckenberger, 2012, Radiotherapy alone for stage I-III low grade follicular lymphoma: long-term outcome and comparison of extended field and total nodal irradiation, Radiat Oncol, 7, 103, 10.1186/1748-717X-7-103

Fakhrian, 2012, Radiotherapy in stage I-III follicular non-Hodgkin lymphoma. Retrospective analysis of a series of 50 patients, Strahlenther Onkol, 188, 464, 10.1007/s00066-011-0057-0

Ahmed, 2013, Early stage W.H.O. grade I and II follicular lymphoma treated with radiation therapy alone, PLoS One, 8, e65156, 10.1371/journal.pone.0065156

Friedberg, 2012, Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study, J Clin Oncol, 30, 3368, 10.1200/JCO.2011.40.6546

Lowry, 2011, Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial, Radiother Oncol, 100, 86, 10.1016/j.radonc.2011.05.013

Hoppe

Petersen, 2004, Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone [abstract], J Clin Oncol, 22, 6521, 10.1200/jco.2004.22.14_suppl.6521

Engelhard, 2011, Follicular lymphoma: curability by radiotherapy in limited stage nodal disease? Updated results of a randomized trial [abstract], Ann Oncol, 22, iv90

Seymour, 2003, Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma, J Clin Oncol, 21, 2115, 10.1200/JCO.2003.07.111

Advani, 2004, Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy, J Clin Oncol, 22, 1454, 10.1200/JCO.2004.10.086

Ardeshna, 2003, Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial, Lancet, 362, 516, 10.1016/S0140-6736(03)14110-4

Brice, 1997, Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte, J Clin Oncol, 15, 1110, 10.1200/JCO.1997.15.3.1110

Young, 1988, The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment, Semin Hematol, 25, 11

Kahl, 2011, Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): a randomized phase iii study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma [abstract], Blood, 118, LBA-6, 10.1182/blood.V118.21.LBA-6.bld0076_P3_LBA-6

Ardeshna, 2014, Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial, Lancet Oncol, 15, 424, 10.1016/S1470-2045(14)70027-0

McLaughlin, 1998, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program, J Clin Oncol, 16, 2825, 10.1200/JCO.1998.16.8.2825

Hainsworth, 2002, Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma, J Clin Oncol, 20, 4261, 10.1200/JCO.2002.08.674

Bachy, 2013, Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma, Haematologica, 98, 1107, 10.3324/haematol.2012.082412

Marcus, 2005, CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma, Blood, 105, 1417, 10.1182/blood-2004-08-3175

Marcus, 2008, Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma, J Clin Oncol, 26, 4579, 10.1200/JCO.2007.13.5376

Hiddemann, 2005, Blood, 106, 3725, 10.1182/blood-2005-01-0016

Herold, 2007, Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study, J Clin Oncol, 25, 1986, 10.1200/JCO.2006.06.4618

Salles, 2008, Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study, Blood, 112, 4824, 10.1182/blood-2008-04-153189

Federico, 2013, R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi, J Clin Oncol, 31, 1506, 10.1200/JCO.2012.45.0866

Rummel, 2013, Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial, Lancet, 381, 1203, 10.1016/S0140-6736(12)61763-2

Flinn, 2014, Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study, Blood, 123, 2944, 10.1182/blood-2013-11-531327

Rummel, 2005, Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma, J Clin Oncol, 23, 3383, 10.1200/JCO.2005.08.100

Robinson, 2008, Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma, J Clin Oncol, 26, 4473, 10.1200/JCO.2008.17.0001

Kahl, 2010, Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study, Cancer, 116, 106, 10.1002/cncr.24714

Morschhauser, 2009, Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence, Oncologist, 14, 17, 10.1634/theoncologist.2009-S2-17

Vitolo, 2013, J Clin Oncol, 31, 3351, 10.1200/JCO.2012.44.8290

Salles, 2011, Rituximab maintenance for 2 years in patients with high tumor burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, Lancet, 377, 42, 10.1016/S0140-6736(10)62175-7

van Oers, 2010, Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study, J Clin Oncol, 28, 2853, 10.1200/JCO.2009.26.5827

Hochster, 2009, Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study, J Clin Oncol, 27, 1607, 10.1200/JCO.2008.17.1561

Forstpointner, 2006, Blood, 108, 4003, 10.1182/blood-2006-04-016725

Morschhauser, 2013, 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial, J Clin Oncol, 31, 1977, 10.1200/JCO.2012.45.6400

Morschhauser, 2008, Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma, J Clin Oncol, 26, 5156, 10.1200/JCO.2008.17.2015

Ladetto, 2008, Blood, 111, 4004, 10.1182/blood-2007-10-116749

Tarella, 2013, Prolonged survival of poor risk follicular lymphoma patients following primary treatment with rituximab-supplemented CHOP or HDS with autograft: long-term results of the multicenter randomized GITMO/FIL trial [abstract], Blood, 122, 551, 10.1182/blood.V122.21.551.551